Dr Joyce Ohm explains how sequencing tumor genomes reveals the mutations needed to design targeted cell and gene therapies for cancer patients. In part 2 of this interview, Joyce Ohm, PhD, explains ...
Dr. Monty Pal begins the discussion on treatment sequencing in advanced renal cell carcinoma (RCC) by emphasizing the ...
Dr. Monty Pal discusses his approach to selecting second-line therapy for advanced renal cell carcinoma (RCC) based on the ...
Betts, MD, discusses how discharging patients as early as day 5 after stem cell transplant has proved feasible and improves quality of life. Brian C. Betts, MD, Vice Chair of Strategic Initiatives for ...
Immunosuppression confers markedly elevated cSCC risk, with transplant recipients experiencing 65- to 100-fold higher ...
Early termination after 68 randomizations reflected a 61% serious AE rate and 19% treatment-related deaths with radiotherapy, ...
FCA lymphodepletion produced dose-limiting toxicities, including grade 3 autoimmune hepatitis and fatal hyperinflammatory ...
A third CRL was issued for rivoceranib plus camrelizumab in first-line unresectable/metastatic HCC, driven by cGMP ...
In an interview with Targeted Oncology, Eunice S. Wang, MD, of Roswell Park Comprehensive Cancer Center, discussed which ...
Dr. Monty Pal discusses how the increasing use of adjuvant immunotherapy has introduced new considerations for the management ...
In this interview with Targeted Oncology managing editor Sabrina Serani, Estelamari Rodriguez, MD, MPH, hematologist-oncologist at Sylvester Comprehensive Cancer Center, discusses ...
Hansen, MD, discusses outcomes from a large retrospective study of patients treated with ciltacabtagene autoleucel for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results